Gain Therapeutics Inc. is a biotechnology firm engaged in the research and development of innovative therapies aimed at treating diseases caused by protein misfolding, with a focus on rare genetic diseases and neurological disorders. Utilizing its Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform, the company identifies allosteric sites on misfolded proteins to discover proprietary small molecules that can bind to these sites, thereby restoring proper protein folding and addressing the underlying disease. Gain Therapeutics' lead product candidate is GT-02287, which targets GBA1 Parkinson's disease. Additionally, the company is advancing structurally targeted allosteric regulator candidates for a range of conditions, including Morquio B, GM1 gangliosidosis, neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics is headquartered in Bethesda, Maryland, and its shares are listed on the NASDAQ under the ticker symbol GANX.

Gain Therapeutics

Gain Therapeutics (GANX) Status Update Summary | Quartr

Google Play

App Store

App links

Article Categories

Prefooter USP - CTA App

Dig deeper into the Visa Inc fundamentals on Quartr.

Features CTA

Product

Use cases

Discover

Resources

Company

email

Features

Platforms

Featured article

Pricing

Contact sales

Simple CTA

events-root

Gain Therapeutics Inc

GT-02287 demonstrates disease-modifying potential in Parkinson's with strong clinical and biomarker data.

Corporate presentation

GT-02287 moves to Phase 1b for Parkinson's, targeting disease modification with broad patient inclusion.

Maxim Group’s 2024 Healthcare Virtual Summit

GT-02287 reduced CSF glucosylsphingosine by 81% and improved UPDRS scores in Parkinson's patients.

Study Update

GT-02287 shows early safety and clinical promise in Parkinson's, with key data due year-end.

Study Result

Shelf registration for up to $100M supports pipeline growth and clinical trials in CNS and rare diseases.

Registration Filing

Up to $100M in securities may be offered to advance a promising Parkinson's therapy and pipeline. 

Annual meeting to vote on directors, auditor, share increase, and governance matters.

Proxy Filing

Key votes include director elections and doubling authorized shares to 100 million.

Votes will be held on director elections, auditor ratification, and doubling authorized shares.

### Management and leadership update
- Interim CEO and CFO roles assumed by Gene Mack following the departure of Matthias Alder.
- Dr. Khalid Islam, founder and chairman, appointed as executive chairman to support management and clinical strategy.
- No changes to business strategy or objectives following management transition.

### Financial and operational highlights
- Raised $11 million in a public offering, netting approximately $10 million after fees.
- Proceeds will fund clinical and non-clinical development of GT-02287 and general corporate purposes.
- Financing enables initiation of a Phase 1b proof-of-concept study in Parkinson's disease patients.

### Clinical development and trial updates
- GT-02287 is in Phase I clinical development for Parkinson's disease.
- Single ascending dose Phase I trial showed GT-02287 was well tolerated with no serious adverse events.
- Multiple ascending dose Phase I trial expected to complete all four cohorts by mid-2024, with top-line data in August and full results at a major conference in September.

Gain Therapeutics (GANX) Status Update summary

Status Update summary

Management and leadership update

Financial and operational highlights

Clinical development and trial updates

Latest events from Gain Therapeutics